International Journal of Pharmaceutical research and Applications
Volume 11, Issue 3, May-June2026, pp:1196-1200 www.ijprajournal.com ISSN:2456-4494

Role of Pharmacist in Deprescribing to Manage Polypharmacy

FARSANA P.M, NAEEM NAVAS.P, APARNA VINOY, STEPHANIE SHAJI, DELPHINA C.P

Department of Pharmacy Practice
Holy grace Academy of Pharmacy, Mala
Thrissur, Kerala

Date of Submission: 12-05-2026 Date of Acceptance: 27-05-2026

Abstract

As the global population ages and chronic multimorbidity rises, polypharmacy—commonly defined as the concurrent use of five or more medications—has become a critical public health challenge. While multi-drug regimens are often clinically well-intentioned, they frequently escalate the risk of adverse drug reactions (ADRs), complex drug-drug interactions, financial burdens, and diminished medication adherence. To counter these risks, deprescribing has emerged as an essential, patient-centered clinical practice.

This report examines the systematic process of deprescribing, emphasizing the pivotal role of the pharmacist in conducting comprehensive medication reviews, identifying potentially inappropriate medications (PIMs), and managing structured drug withdrawal. It highlights evidence-based screening tools (such as the Beers and STOPP/START criteria) and explores the nuances of managing high-risk drug classes across vulnerable populations, including the frail elderly, patients with dementia, and those in palliative care. Finally, we address the critical communication strategies, withdrawal management protocols, and systemic public health frameworks required to successfully integrate pharmacist-led deprescribing into modern healthcare systems.

Key Keywords

Deprescribing
Polypharmacy
Pharmacist Interventions
Medication Review
Potentially Inappropriate Medications (PIMs)
Patient Safety
Geriatric Care
Drug Burden Index (DBI)

I. Introduction

Modern medicine excels at introducing therapies to manage chronic conditions, yet it frequently fails to re-evaluate whether these therapies remain appropriate over time. Polypharmacy is particularly prevalent among older adults and individuals navigating complex, multi-system diseases. Left unmanaged, it shifts from a therapeutic necessity to a clinical hazard, resulting in a cascade of prescribing errors, heightened institutionalization rates, and increased healthcare expenditures.

Deprescribing is not a casual cessation of treatment; it is a deliberate, highly structured, and evidence-based process of tapering or stopping medications where the potential for harm outweighs the potential for benefit. By reframing patient care around current life expectancy, functional status, and personal goals, deprescribing serves as a vital tool for optimizing patient safety and restoring rational drug use.

II. The Pharmacist's Role in the Deprescribing Ecosystem

Pharmacists possess specialized expertise in pharmacokinetics and pharmacodynamics, positioning them as ideal leaders for deprescribing initiatives. Operating at the intersection of patients, physicians, and community care, pharmacists translate complex pharmacological data into actionable clinical decisions.

Beyond simply flagging redundant or harmful medications, pharmacists bridge critical gaps in care by:

Deconstructing prescribing cascades (where a new drug is mistakenly prescribed to treat the side effect of an existing one).

Aligning complex drug regimens with a patient's evolving therapeutic goals.

Serving as a direct liaison between multiple specialized physicians to ensure cohesive medication management.

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 3, May-June2026, pp:1196-1200 www.ijprajournal.com ISSN:2456-4494

III. Evidence-Based Clinical Guidelines & Screening Tools

To ensure clinical objectivity, pharmacists utilize validated screening frameworks to identify Potentially Inappropriate Medications (PIMs) and calculate cumulative medication risks.

Beers Criteria (American Geriatrics Society)

A globally recognized directory of medications that should generally be avoided or used with extreme caution in older adults. It highlights drugs with unfavorable risk-benefit profiles, such as long-acting benzodiazepines and certain tricyclic antidepressants.

STOPP/START Criteria

STOPP (Screening Tool of Older Persons' Prescriptions): Identifies specific, clinically significant drug-drug or drug-disease interactions where discontinuation is warranted.

START (Screening Tool to Alert to Right Treatment): Balances the process by identifying omitted, clinically indicated medications, ensuring that deprescribing does not lead to undertreatment.

Drug Burden Index (DBI)

A formal mathematical model that measures a patient's total cumulative exposure to anticholinergic and sedative medications. High DBI scores are strongly correlated with functional decline, cognitive impairment, and a significantly increased risk of falls in geriatric populations.

IV. The 5-Step Clinical Process of Deprescribing

Deprescribing is executed through a systematic, cyclical five-step framework designed to guarantee patient safety at every phase:

Comprehensive Medication Review: Compiling an exhaustive history of all prescription drugs, over the counter (OTC) products, and herbal supplements the patient is currently taking.

Risk & Benefit Assessment: Evaluating each medication against current clinical guidelines, life expectancy, treatment targets, and potential PIM status.

Prioritization of Targets: Ranking medications for discontinuation based on their potential for immediate harm, the level of patient distress they cause, and the ease of safe withdrawal.

Formulating a Tapering Plan: Developing a customized, gradual dose-reduction schedule tailored to the patient's physiological tolerance to prevent severe withdrawal or rebound phenomena.

Continuous Monitoring & Feedback Loops: Establishing an ongoing review schedule to monitor clinical markers, track the recurrence of original symptoms, and provide psychological support to the patient

V. Tailoring Interventions for Special and Vulnerable Populations

Deprescribing is never a one-size-fits-all practice; it demands acute clinical judgment when applied to highly vulnerable patient cohorts:

The Frail Elderly: Aging alters hepatic metabolism and renal clearance, dramatically compounding drug toxicity risks. Pharmacists focus heavily on eliminating drugs that impair mobility, compromise balance, or directly contribute to catastrophic fall injuries.

Patients with Dementia & Cognitive Decline: In advanced cognitive impairment, long-term preventative therapies (such as aggressive lipid-lowering or tight glycemic control) yield minimal clinical utility while imposing high daily administration burdens. Pharmacists prioritize minimizing sedatives, antipsychotics, and anticholinergics that exacerbate confusion and delirium.

Palliative and End-of-Life Care: Here, the therapeutic paradigm shifts entirely from preventative medicine to intensive symptom management and maximizing quality of life. Pharmacists actively discontinue burdensome, non-essential maintenance drugs while optimizing therapies dedicated to comfort, pain management, and dignity.

VI. Communication, Shared Decision-Making, and Behavioral Changes

The technical ability to deprescribe is irrelevant without the communication skills needed to navigate patient anxiety and professional hesitation. Successful deprescribing relies heavily on shared decision-making.

Frameworks & Communication Tools

The Three-Talk Model: Pharmacists structure clinical conversations into three distinct phases: Team Talk (inviting the patient into the decision-making partnership), Option Talk (clearly discussing the risks of continuing vs. stopping a drug), and Decision Talk (constructing a mutually agreed-upon tapering plan).

Motivational Interviewing: By deploying open-ended questions and reflective listening, pharmacists explore patient ambivalence, address deep-seated fears of illness relapsing, and build trust.

The Teach-Back Method: Asking patients or caregivers to explain the tapering steps in their own

International Journal of Pharmaceutical research and Applications
Volume 11, Issue 3, May-June2026, pp:1196-1200 www.ijprajournal.com ISSN:2456-4494

words ensures complete comprehension and reduces post-discharge medication errors.

Overcoming Clinical Barriers

For Patients: Address psychological dependence and the fear that stopping a drug means their provider is "giving up" on them.

For Physicians: Overcome prescribing inertia—the hesitation to alter a medication regimen initiated by another specialist—by presenting clear, evidence-based rationales for discontinuation.

VII. Strategic Management of Withdrawal and Rebound Effects

Abruptly discontinuing certain medications can trigger severe physiological backlashes. Pharmacists are essential in anticipating, identifying, and mitigating these withdrawal and rebound syndromes.

High-Risk Drug Class Potential Withdrawal / Rebound Syndrome Pharmacist Mitigation Strategy

Benzodiazepines Severe anxiety, profound insomnia, tremors, and potential seizures. Ultraslow dose reduction over months; psychological support; potential substitution with long-acting alternatives during the taper.

Proton Pump Inhibitors (PPIs) Hyperacidity rebound, severe dyspepsia, and return of GERD symptoms. Step-down tapering regimens; temporary PRN utilization of H2 receptor antagonists or antacids.

Beta-Blockers Rebound tachycardia, severe hypertension, and acute ischemic events. Gradual down-titration alongside close, daily monitoring of heart rate and blood pressure metrics.

Antidepressants (SSRIs/SNRIs) Discontinuation syndrome (dizziness, paresthesia, vivid dreams, irritability). Highly customized, incremental liquid or micro-dose tapering plans over extended timelines.

VIII. Seamless Implementation of Clinical Deprescribing Services

Transitioning deprescribing from an occasional intervention into an everyday standard of care requires structural workflow integration:

Targeted Patient Identification: Leveraging algorithmic screening within Electronic Health Records (EHR) to flag high-risk profiles automatically (e.g., patients over 75 taking more than eight chronic medications).

Point-of-Care Digital Tools: Embedding integrated Beers or STOPP/START clinical decision support systems directly into pharmacy and physician software interfaces to provide real time alerts.

Interdisciplinary Communication Loops: Establishing standardized, closed-loop referral templates that allow community pharmacists to seamlessly deliver deprescribing recommendations directly to primary care physicians for rapid approval.

IX. Continuous Monitoring and Metrics for Outcome Evaluation

To justify the expansion of pharmacist-led deprescribing services, healthcare systems must meticulously track process and outcome metrics:

Process Metrics (Inputs & Activities): Tracking the number of high-risk patients identified, total medication reviews performed, and the acceptance rate of pharmacist recommendations by prescribing physicians.

Clinical Outcome Metrics: Documenting long-term reductions in total daily pill burdens, declines in documented adverse drug events, drops in fall-related emergency room admissions, and measurable improvements in patient-reported quality-of-life scores.

X. Public Health, Policy, and Community Integration

To achieve widespread impact, deprescribing must move beyond clinic walls and integrate into broader public health frameworks.

Public Awareness Campaigns: Educating communities to dismantle the misconception that "more pills equal better health." Shifting public perception empowers patients to actively ask their doctors: "Do I still need to take this medication?"

Professional Education Standards: Integrating mandatory training on polypharmacy management and deprescribing methodologies directly into medical, nursing, and pharmacy school curricula.

Systemic Policy Integration: Advocating for healthcare reimbursement models that financially compensate pharmacists for the cognitive clinical labor of medication optimization, rather than tying revenue solely to the volume of medications dispensed.

XI. Conclusion

Deprescribing represents a critical, evidence-based evolution in modern therapeutics, countering the silent epidemic of polypharmacy. Far from a simple rollback of care, it is a highly skilled, patient-centric intervention that restores safety and intentionality to pharmacotherapy.

As experts in drug mechanics, pharmacists are uniquely qualified to lead this movement—identifying risks, designing precise tapering schedules, and managing clinical withdrawal. By systematically integrating pharmacist-led deprescribing into primary care networks, long-term care facilities, and community health programs, modern medicine can dramatically reduce adverse drug events, curtail unnecessary healthcare expenditures, and profoundly improve the daily quality of life for vulnerable populations worldwide.

REFERENCES

[1]. World Health Organization. WHO Centre for Health Development. A glossary of terms for community health care and services for older people. Kobe: World Health Organization Centre for Health Development; 2004.
[2]. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am AcadNurse Pract. 2005;17(4):123–132.
[3]. Hovstadius B, Astrand B, Petersson G. Dispensed drugs and multiple medications in
[4]. the Swedish population: an individual-based register study. BMC Clin Pharmacal. 2009;9:11.
[5]. NHS Specialist Pharmacy Service. Understanding polypharmacy, overprescribing and
[6]. deprescribing. London: NHS Specialist Pharmacy Service; 2025.
[7]. Monash University. The ethics of deprescribing in older adults. Melbourne: Monash University; 2024.
[8]. Mannucci PM, Nobili A, Pasina L, et al. Polypharmacy in older people. Intern Emerg Med. 2018;13(6):865 872.
[9]. Reeve E, Denig P, Hilmer SN, ter Meulen R. The ethics of deprescribing in olderadults. J Bioeth Inq. 2016;13(4):581–590.
[10]. Onder G, Vetrano DL, Palmer K, et al. Italian guidelines on management of persons with multimorbidity and polypharmacy. Rome: Italian Ministry of Health; 2013.
[11]. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management. NICE guideline [NG56]. London: NICE; 2016.
[12]. Handler SM, Wright RM, Ruby CM, et al. Epidemiology of medication-related adverse events in nursing homes. Am J Geriatr Pharmacother. 2006;4(3):264–272.
[13]. Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medication in the elderly: the PRISCUS list. DtschArztebl Int. 2010;107(31–32):543–551.
[14]. Young EH, Pan S, Yap AG, et al. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. J Am Pharm Assoc. 2021;61(1)–e7.
[15]. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–543.
[16]. NHS City and Hackney Clinical Commissioning Group. High risk drugs and vulnerable patients: prescribing guidance. London: NHS City and Hackney CCG; 2016 [17/05, 5:26 pm] Navas:
[17]. Reeve E, Gnjidic D, Long J, et al. A systematic review of the emerging definition of
[18]. deprescribing with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–1268.
[19]. National Institute for Health and Care Excellence. Medication optimisation: the safe and effective use of medicines to enable the best possible outcomes. London: NICE; 2015.
[20]. Vanderman AJ, Moss JM, Bryan WE, et al. Evaluating the impact of medication safety alerts on prescribing potentially inappropriate medications for older veterans in an ambulatory care setting. J Pharm Pract. 2017;30(1):82–88.
[21]. Egbert N, Nanna KM. Health literacy: challenges and strategies. Online J Issues Nurs. 2009;14(3) 1.
[22]. Agrawal A, Pergadia ML, Lynskey MT. Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions? Am J Addict. 2008;17(3):199–208.
[23]. Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat. 1991;8(1–2):19 28.
[24]. World Health Organization. Medication safety in polypharmacy: medication without harm. Geneva: World Health Organization; 2019.
[25]. Wang Z, Liu T, Su Q, et al. Prevalence of polypharmacy in the elderly population
[26]. worldwide: a systematic review and meta-analysis. J GerontolA Biol Sci Med Sci. 2022;77(4):759–767.
[27]. Canadian Institute for Health Information. Drug use among seniors in Canada, 2016.

[28]. Ottawa: Canadian Institute for Health Information; 2018.
[29]. American Geriatrics Society Beers Criteria® Update Expert Panel. American.Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694.
[30]. Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology, and consequences. EurGeriatr Med. 2021;12(3):443–452.